Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Gets Approval For US Pegfilgrastim

Becomes First To Offer Both Long- And Short-Acting Biosimilars

Executive Summary

Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”

You may also be interested in...



Amgen Pulled Up Over Anti-Biosimilar Pegfilgrastim Promotion

Amgen has been rebuked by the FDA over promotion for its unique Neulasta Onpro on-body injector version of pegfilgrastim, in which the firm made false or misleading claims about its benefit compared to a pre-filled syringe formulation of pegfilgrastim, where biosimilar competition exists.

Lupin’s Pegfilgrastim Biosimilar Accepted By US FDA

Lupin’s first US biosimilar application, for a rival to Neulasta, has been accepted for filing by the FDA. If approved, the product would join an already crowded market for pegfilgrastim in the US.

Sandoz Is Satisfied With US Pegfilgrastim Start

Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel